BeauBrain Healthcare

What BeauBrain Healthcare does

BeauBrain Healthcare is a Seoul-based medical AI company founded in February 2022 that develops deep learning algorithms to predict Alzheimer's disease biomarkers from brain imaging and cognitive data, with the stated mission of shifting dementia care from post-onset treatment to early prediction and prevention. The company's core technology predicts ATN (Amyloid Beta, Tau, Neurodegeneration) biomarkers using routine 2D MRI/CT scans alone, eliminating dependence on expensive PET imaging — a capability validated on datasets drawn from Samsung Medical Center including 7,000+ amyloid PET cases, 30,000+ MRI/CT cases, and 30,000+ genomic profiles.

The product portfolio spans three diagnostic solutions (BeauBrain Amylo for PET amyloid quantification with Korean MFDS Class II certification; Morph for 2D MRI brain atrophy analysis with FDA 510(k) filing pending; SCST tablet-based cognitive assessment) and a digital therapeutics ecosystem under the PASCAL brand (mobile trainer app, neuropsychologist-managed @home program, @hospital clinical rehabilitation, and Fitness Center). The company reports AUC up to 0.95 for amyloid prediction and 0.86 for tau prediction, with over 500 enrolled PASCAL@Home participants as of April 2025.

Revenue is generated through five streams: B2B SaaS/per-test licensing to hospitals and clinics, B2C subscriptions for PASCAL cognitive training, technology licensing to pharmaceutical partners (notably Daewoong Pharmaceutical), professional services and clinical validation support, and distribution margins on C2N Diagnostics' PrecivityAD2 blood test in South Korea. Go-to-market combines direct enterprise sales to hospitals and academic medical centers, channel partnerships for international expansion (planned U.S. entry via academic medical centers, Israel KSC program), and B2C digital health marketing for the PASCAL platform. Named institutional customers include Samsung Medical Center, Seoul National University Bundang Hospital, and government dementia care centers in Geumcheon-gu and Gangnam-gu.

Name

BeauBrain Healthcare

Legal name

주식회사 뷰브레인헬스케어 (BeauBrain Healthcare)

Website

https://beaubrain.bio

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

BeauBrain Healthcare is a Seoul-based medical AI company developing deep learning algorithms that predict Alzheimer's biomarkers (amyloid, tau, neurodegeneration) from routine brain MRI/CT scans. It serves hospitals, memory clinics, and at-risk consumers through AI diagnostic software and the PASCAL digital cognitive training platform.

Ownership category

akta.pro rank

Product category

Medical AI Diagnostic Software

NAICS

Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

Keywords

• Medical imaging AI
• Alzheimer's diagnostics
• Digital therapeutics
• Brain health software
• Cognitive assessment tools

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. B2B Medical AI Software (SaaS/Per-test Licensing): Hospital and clinic subscriptions for AI diagnostic tools (Amylo, Morph, SCST). Revenue from medical institutions using AI image analysis for clinical decision support. KRW 100M+ amyloid PET test cost context suggests significant pricing power for AI-based alternatives. Government reimbursement listing being pursued.
2. B2C Digital Therapeutics (PASCAL): Mobile app-based cognitive training programs (PASCAL Trainer) and premium PASCAL@Home services with neuropsychologist-led 1:1 management. Premium program targets high-risk normal individuals. Growing participant base of 500+ as of April 2025.
3. Technology Licensing to Pharma Partners: Licensing of proprietary AI diagnostic algorithms and data platforms to pharmaceutical partners. Daewoong Pharmaceutical has rights to license, transfer, co-market, or sell BeauBrain products. Long-term data partnership with Samsung Medical Center.
4. Professional Services & Clinical Trial Support: Implementation support, clinical validation studies, and consulting services for healthcare institutions adopting BeauBrain solutions. Partnership with Korean Health Industry Promotion Agency for regulatory consulting.
5. Distribution Revenue (C2N Partnership): Commercial distribution of C2N Diagnostics' PrecivityAD2 blood test to Korean medical institutions. Revenue derived from distribution margins on the blood-based Alzheimer's diagnostic test.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

BeauBrain Healthcare develops and sells AI-powered medical software for early Alzheimer's disease prediction and prevention. Its core diagnostic offerings include BeauBrain Amylo (PET-CT/PET-MRI amyloid beta quantification), Morph (2D MRI brain atrophy analysis), and SCST (tablet-based cognitive assessment), sold to hospitals, memory clinics, and government screening programs. The company also operates the PASCAL digital therapeutics ecosystem of mobile and clinical cognitive training products sold to at-risk consumers and clinical institutions.

Product overview

BeauBrain Healthcare offers a multi-product AI-powered platform for early Alzheimer's disease prediction and prevention, consisting of three core diagnostic solutions and a digital therapeutics ecosystem. The core diagnostic products include BeauBrain Amylo (AI-based PET-CT/PET-MRI image analysis for amyloid quantification), Morph (deep learning-based 2D MRI brain atrophy analysis), and SCST (tablet-based digital cognitive assessment). These are complemented by the PASCAL digital therapeutics ecosystem comprising PASCAL Trainer (mobile cognitive training app), PASCAL @home (neuropsychologist-managed training program), PASCAL @hospital (clinical cognitive rehabilitation), and Brainmee (B2C brain health management program). The platform integrates AI-driven predictive analytics to forecast ATN (Amyloid Beta, Tau, Neurodegeneration) biomarkers, enabling a shift from post-onset treatment to early diagnosis and prevention.

Differentiator

Problem solved

Functional benefit

Brands

• BeauBrain Amylo: PET-CT/PET-MRI brain image analysis solution that quantifies amyloid beta biomarkers using SUVR and Centiloid methods
• Morph
• SCST (Seoul Cognitive Status Test)
• PASCAL Trainer
• PASCAL @home
• PASCAL @hospital
• SCST
• BeauBrain Trainer

Products and services

• BeauBrain Amylo AI-based PET-CT and PET-MRI brain image analysis software that quantifies amyloid beta biomarkers using SUVR and Centiloid methods to support Alzheimer's disease diagnosis. Analyzes six brain regions including Striatum without requiring 3D MRI and provides disease severity reading and prognosis prediction. Sold to hospitals, neurology departments, and memory clinics for clinical Alzheimer's diagnostic use.
• Morph Deep learning-based 2D MRI brain atrophy quantification software that segments the brain into 14 sub-regions, providing volume values and percentile scores based on normal population standards to predict Alzheimer's disease classification, dementia risk index, brain age, and amyloid beta positivity. Sold to hospitals and clinics for scalable brain atrophy monitoring without requiring 3D MRI.
• SCST (Seoul Cognitive Status Test) Tablet-based digital cognitive function assessment solution that evaluates five cognitive domains (memory, attention/concentration, visuospatial ability, executive function, and language) with automated scoring and real-time analysis across six cognitive domains in approximately 30 minutes. Sold to hospitals, dementia care centers, and government public health screening programs.
• PASCAL Trainer Mobile brain health trainer application that provides cognitive training through 16 exercises across 5 cognitive domains (language, memory, calculation, attention, visuospatial, executive function) with weekly personalized problem calibration, gamification, rewards, and randomized controlled trial-validated efficacy. Sold direct-to-consumer via mobile app subscription.
• PASCAL @home Mobile-based premium 12-week cognitive training service combining app-based cognitive training with offline group activities, lectures, and events, delivered with 1:1 neuropsychologist management. Sold as a premium B2C subscription to high-risk normal individuals aged 50+ for dementia prevention and brain health management.
• PASCAL @hospital Computerized (tablet or desktop) cognitive rehabilitation treatment service for clinical use within hospitals and medical institutions, part of the PASCAL platform for hospital-based cognitive training delivery.
• Brainmee (브레인미인) B2C brain health management program offering personalized human-centered care for national brain health management, as part of the broader PASCAL platform for dementia prevention and treatment. Sold to individual consumers seeking personalized brain wellness management.
• PrecivityAD2 Blood Test Distribution Commercial distribution of C2N Diagnostics' PrecivityAD2 blood-based Alzheimer's diagnostic test to Korean medical institutions. The test detects amyloid beta protein through a blood sample, achieving 91% accuracy, 90% sensitivity, and 92% specificity in clinical validation studies published in npj Dementia and JAMA, as a less burdensome alternative to expensive amyloid PET scans for patients 50+ with cognitive impairment.

Quantifiable outcome

• 91% accuracy, 90% sensitivity, 92% specificity in detecting amyloid plaques compared to amyloid PET imaging (PrecivityAD2 via C2N partnership)
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• C2N DiagnosticscoreChannel Partner/ Reseller/ Distributor · 11 March 2026BeauBrain entered a commercial distribution partnership with C2N Diagnostics to supply the PrecivityAD2 blood test for Alzheimer's disease diagnosis to Korean medical institutions. The test detects amyloid beta protein through a blood sample as a less burdensome alternative to expensive amyloid PET tests, targeting patients 50+ with cognitive decline symptoms. C2N's test achieved 91% accuracy, 90% sensitivity, and 92% specificity in clinical validation studies. C2N has FDA Breakthrough Device designation and is under FDA review for formal license approval.
• Israel KSC (Korea Startup Center) Global Acceleration ProgramminorGTM or Marketing Partner · 18 September 2023Selected for the 2023 KSC Global Acceleration Program organized by the Ministry of SMEs and Startups. Participated in Israel Demo Day in Tel Aviv for investor pitching and global partner discovery. Program connects Korean MedTech/HealthTech startups with potential partners, investors, channels, and clinical specialists internationally.
• Samsung Medical Center / Sungkyunkwan UniversitycoreStrategic or Co-development PartnerBeauBrain was co-founded by Dr. Duk Lyul Na and Dr. Sang Won Seo from Samsung Medical Center Neurology Department. The company leverages Samsung Medical Center's clinical data (7,000+ amyloid PET, 30,000+ MRI/CT, 30,000+ genomic profiles) for AI model training. Joint research projects and clinical trials are conducted. Samsung Life Welfare Foundation holds 5% equity stake.
• InfoBankminorImplementation/ SI/ Consulting PartnerInfoBank acts as the TIPS (Tech Incubator Program for Startups) operator. Provides fast-track designation (July 2022), mentorship, commercialization support, and investment attraction assistance for BeauBrain.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• C2N Diagnostics: C2N Diagnostics commercializes the PrecivityAD blood test for amyloid detection in Alzheimer's disease. Directly comparable to BeauBrain as an Alzheimer's-specific biomarker diagnostics company; the two are also commercial partners (BeauBrain distributes PrecivityAD2 in Korea), making them simultaneously collaborator and competitor in blood vs. imaging-based diagnostic modalities.
• Neurotrack Technologies: Neurotrack develops digital cognitive assessment tools for early Alzheimer's detection and memory health. Directly comparable to BeauBrain's SCST and PASCAL cognitive testing/training suite, addressing the same clinical workflow of screening and monitoring at-risk individuals for cognitive decline.
• Linus Health: Linus Health offers AI-powered digital cognitive assessment (e.g., DCTclock) for early detection of Alzheimer's and other dementias. Closely comparable to BeauBrain's SCST tablet-based cognitive test and broader ATN-driven digital diagnostics strategy targeting primary care and specialty memory clinics.
• Altoida: Altoida provides AI-based digital biomarkers using smartphone and AR-based cognitive assessments to predict MCI and Alzheimer's risk. Comparable to BeauBrain's PASCAL mobile cognitive platform and SCST assessment, both targeting early Alzheimer's identification and brain health monitoring.
• BrainCheck: BrainCheck delivers tablet- and web-based cognitive assessment tools for clinicians to screen and monitor cognitive impairment including Alzheimer's. Comparable to BeauBrain SCST in offering digital cognitive screening with automated scoring for clinical and senior care settings.

Emerging players

• Darmiyan: Darmiyan is an early-stage company developing AI-based brain imaging analysis for early Alzheimer's disease detection. Comparable to BeauBrain's Morph and Amylo imaging SaMD products, with a narrower initial focus on MRI-based brain age and microstructural analysis.

Broad incumbents

• Fujirebio: Fujirebio (H.U. Group) is a major established diagnostics company with FDA-cleared Lumipulse blood-based amyloid and tau assays for Alzheimer's. Comparable to BeauBrain's biomarker diagnostics franchise, but operating at global scale across multiple neurodegenerative disease markers rather than a single integrated platform.
• Eisai: Eisai is the manufacturer of Leqembi, the first FDA-approved disease-modifying Alzheimer's therapy, and is investing heavily in companion diagnostics and biomarker infrastructure. Comparable as a major stakeholder in the Alzheimer's diagnostic + therapeutic ecosystem where BeauBrain operates, though Eisai is primarily a pharmaceutical incumbent rather than a diagnostics specialist.
• Biogen: Biogen develops and commercializes Alzheimer's therapeutics (Aduhelm, Leqembi co-marketing) and has companion diagnostic partnerships with blood and imaging biomarker developers. Comparable as a strategic player in the Alzheimer's diagnostic + therapeutic stack, where BeauBrain's tools could serve as patient identification and monitoring solutions.

Others

• Quanterix: Quanterix provides ultra-sensitive Simoa biomarker detection platforms widely used in Alzheimer's and neurodegeneration research and clinical trials. Comparable as an enabling biomarker technology provider in the same ATN biomarker landscape BeauBrain targets, rather than a direct diagnostic product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BeauBrain Healthcare